Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOPIN: Hepatic Percutaneous Perfusion plus Ipilimumab and Nivolumab in Metastatic Uveal Melanoma
2024-516127-14-01Phase 2Authorised
- Sponsor
- Leiden University Medical Center
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ipilimumab, nivolumab and melphalan in intraocular melanoma (3 arms), sponsored by Leiden University Medical Center. Primary endpoints: Safety and feasibility (Phase 1b) and Progression-free survival at one year (Phase 2). Planned start Sep 2024; status: authorised.
02
Drugs
03
Conditions
intraocular melanoma
Beyond the preview
Go deeper on 2024-516127-14-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516127-14-01.